Evidence map›Paper›PMID 38866877›Full record

ArticleScientific reports2024

Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway.

Salma A El-Marasy, Mona M AbouSamra, Passant E Moustafa, Hoda B Mabrok, Omar A Ahmed-Farid, Asmaa F Galal, Hadir Farouk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Salma A El-MarasyDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt. salma_el_marasy@hotmail.com.
Mona M AbouSamraPharmaceutical Technology Department, Pharmaceutical Drug Industries Research Institute, National Research Centre, Giza, Egypt.
Passant E MoustafaDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Hoda B MabrokNutrition and Food Science Department, Food Industries and Nutrition Research Institute, National Research Centre, Giza, Egypt.
Omar A Ahmed-FaridDepartment of Physiology, Egyptian Drug Authority, Giza, Egypt.
Asmaa F GalalNarcotics, Ergogenics and Poisons Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Hadir FaroukDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.

Funding

National Research Centre 12060150
6 · The paper itself

Abstract

Naringenin (NAR) has various biological activities but low bioavailability. The current study examines the effect of Naringenin-loaded hybridized nanoparticles (NAR-HNPs) and NAR on depression induced by streptozotocin (STZ) in rats. NAR-HNPs formula with the highest in vitro NAR released profile, lowest polydispersity index value (0.21 ± 0.02), highest entrapment efficiency (98.7 ± 2.01%), as well as an acceptable particle size and zeta potential of 415.2 ± 9.54 nm and 52.8 ± 1.04 mV, respectively, was considered the optimum formulation. It was characterized by differential scanning calorimetry, examined using a transmission electron microscope, and a stability study was conducted at different temperatures to monitor its stability efficiency showing that NAR-HNP formulation maintains stability at 4 °C. The selected formulation was subjected to an acute toxicological test, a pharmacokinetic analysis, and a Diabetes mellitus (DM) experimental model. STZ (50 mg/kg) given as a single i.p. rendered rats diabetic. Diabetic rat groups were allocated into 4 groups: one group received no treatment, while the remaining three received oral doses of unloaded HNPs, NAR (50 mg/kg), NAR-HNPs (50 mg/kg) and NAR (50 mg/kg) + peroxisome proliferator-activated receptor-γ (PPAR-γ) antagonist, GW9662 (1mg/kg, i.p.) for three weeks. Additional four non-diabetic rat groups received: distilled water (normal), free NAR, and NAR-HNPs, respectively for three weeks. NAR and NAR-HNPs reduced immobility time in forced swimming test and serum blood glucose while increasing serum insulin level. They also reduced cortical and hippocampal 5-hydroxyindoeacetic acid, 3,4-Dihydroxy-phenylacetic acid, malondialdehyde, NLR family pyrin domain containing-3 (NLRP3) and interleukin-1beta content while raised serotonin, nor-epinephrine, dopamine and glutathione level. PPAR-γ gene expression was elevated too. So, NAR and NAR-HNPs reduced DM-induced depression by influencing brain neurotransmitters and exhibiting anti-oxidant and anti-inflammatory effects through the activation PPAR-γ/ NLRP3 pathway. NAR-HNPs showed the best pharmacokinetic and therapeutic results.

Indexed as

Antidepressive AgentsDiabetes Mellitus, ExperimentalFlavanonesNanoparticlesNLR Family, Pyrin Domain-Containing 3 ProteinPPAR gammaAnilidesAnimalsDepressionMaleRatsRats, WistarSignal TransductionStreptozocin2-chloro-5-nitrobenzanilideAnilidesAntidepressive AgentsFlavanonesnaringeninNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratPPAR gammaStreptozocin

Identifiers

PMID38866877
PMCPMC11169681

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.